Dimensional Fund Advisors LP Raises Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Dimensional Fund Advisors LP grew its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLAFree Report) by 5.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,170,829 shares of the company’s stock after purchasing an additional 60,748 shares during the quarter. Dimensional Fund Advisors LP owned approximately 1.31% of Intellia Therapeutics worth $35,704,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. Los Angeles Capital Management LLC grew its holdings in shares of Intellia Therapeutics by 3.7% during the fourth quarter. Los Angeles Capital Management LLC now owns 11,695 shares of the company’s stock worth $357,000 after purchasing an additional 422 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its holdings in shares of Intellia Therapeutics by 7.3% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,651 shares of the company’s stock worth $210,000 after purchasing an additional 451 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of Intellia Therapeutics by 1.8% during the third quarter. Victory Capital Management Inc. now owns 27,316 shares of the company’s stock worth $864,000 after purchasing an additional 470 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Intellia Therapeutics by 7.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 8,144 shares of the company’s stock worth $248,000 after purchasing an additional 582 shares during the last quarter. Finally, Axxcess Wealth Management LLC grew its holdings in shares of Intellia Therapeutics by 4.0% during the fourth quarter. Axxcess Wealth Management LLC now owns 15,592 shares of the company’s stock worth $475,000 after purchasing an additional 594 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Insider Buying and Selling

In related news, EVP James Basta sold 2,297 shares of Intellia Therapeutics stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $32.99, for a total transaction of $75,778.03. Following the completion of the transaction, the executive vice president now directly owns 81,571 shares in the company, valued at approximately $2,691,027.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 3.00% of the company’s stock.

Wall Street Analysts Forecast Growth

NTLA has been the topic of a number of research reports. The Goldman Sachs Group lowered Intellia Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $136.00 to $32.00 in a report on Friday, February 23rd. Wolfe Research initiated coverage on Intellia Therapeutics in a report on Thursday, February 15th. They set a “peer perform” rating on the stock. Wedbush reissued a “neutral” rating and set a $29.00 price target on shares of Intellia Therapeutics in a report on Tuesday, April 23rd. Citigroup lowered their price target on Intellia Therapeutics from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Friday, May 10th. Finally, StockNews.com raised Intellia Therapeutics to a “sell” rating in a report on Friday, May 10th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $66.77.

View Our Latest Research Report on NTLA

Intellia Therapeutics Trading Down 3.3 %

NTLA stock opened at $21.38 on Friday. Intellia Therapeutics, Inc. has a 12-month low of $19.37 and a 12-month high of $47.48. The company has a market cap of $2.06 billion, a price-to-earnings ratio of -3.99 and a beta of 1.85. The firm has a 50 day moving average of $24.09 and a 200-day moving average of $27.07.

Intellia Therapeutics (NASDAQ:NTLAGet Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($1.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.35) by $0.29. Intellia Therapeutics had a negative return on equity of 45.35% and a negative net margin of 893.34%. The firm had revenue of $28.94 million during the quarter, compared to the consensus estimate of $15.60 million. Sell-side analysts forecast that Intellia Therapeutics, Inc. will post -5.12 earnings per share for the current fiscal year.

Intellia Therapeutics Profile

(Free Report)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

Read More

Institutional Ownership by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.